Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-BCDR in Relapsed/Refractory Multiple Myeloma
NCT05376345Phase 1Completed
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-BCDR cells in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Incidence, severity, and type of treatment-emergent adverse events at 2 years, Recommended Phase 2 dose finding at 30 days and 2 more. Started Sep 2022; status: completed.
02
Drugs
LCAR-BCDR cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05376345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376345.